Despite growth in value-based programs, there are still many foundational barriers preventing further adoption. Join industry experts from NantHealth and...
The COVID-19 pandemic has spurred a movement of online health disinformation, leaving consumers and patients to wonder what online information...
The complexity of cancer care continues to increase, and payers are under pressure to balance the dramatic rise in costs...
Professional burnout in the healthcare industry is increasingly challenging, and the COVID-19 pandemic added stressors to clinicians’ already busy workloads....
While many payer and provider organizations have found early success with value-based efforts, barriers around data interoperability still prevent the...
Strategic use of biosimilars in cancer care provides an opportunity for more value as these drugs frequently cost less than...
The cost of oncology-focused drugs in the U.S. has now exceeded $56 billion and the median annual expense of a new cancer...
Authorizations are among the most manual and costly transactions for health plans and providers alike. Health plans spend a significant...
Approximately 60 percent of U.S. companies are partially or fully self-funding their health plans. With more than a third of...
Technology continues to push the envelope, spurring health care’s continuous evolution. Crises like COVID-19 only reinforce the need for the...
Over the past few months, we’ve seen a fundamental shift in healthcare. With this change comes a host of uncertainty...
NantHealth recently hosted a webinar entitled “The Science Behind Emerging Treatments: A COVID-19 Discussion,” with NantHealth Chief Medical Officer, Dr....